# A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis

> **NCT06224192** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 151 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **COMBINATION_PRODUCT:** Rocatinlimab Prefilled Syringe
- **COMBINATION_PRODUCT:** Rocatinlimab AI

## Key facts

- **NCT ID:** NCT06224192
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-02
- **Primary completion:** 2025-04-11
- **Final completion:** 2026-03-16
- **Target enrollment:** 151 (ACTUAL)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06224192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06224192, "A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06224192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*